

Sheng-Shun Yang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/382834/publications.pdf>

Version: 2024-02-01

97
papers

3,530
citations

236925

25
h-index

144013

57
g-index

99
all docs

99
docs citations

99
times ranked

4454
citing authors

#	ARTICLE	IF	CITATIONS
1	Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment. <i>Gut</i> , 2022, 71, 176-184.	12.1	28
2	Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR). <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1151-1162.e6.	4.4	14
3	Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4, 5, 6 infection: Real-world evidence from a nationwide registry in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 1567-1578.	1.7	2
4	Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals. <i>Viruses</i> , 2022, 14, 333.	3.3	2
5	Grazoprevir/Elbasvir Treatment in Liver or Kidney Transplant Recipients with Genotype 1b Hepatitis C Virus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0200321.	3.2	2
6	Critically-Ill Patients with Biliary Obstruction and Cholangitis: Bedside Fluoroscopic-Free Endoscopic Drainage versus Percutaneous Drainage. <i>Journal of Clinical Medicine</i> , 2022, 11, 1869.	2.4	2
7	Efficacy of Lenvatinib and Sorafenib in the Real-World First-Line Treatment of Advanced-Stage Hepatocellular Carcinoma in a Taiwanese Population. <i>Journal of Clinical Medicine</i> , 2022, 11, 1444.	2.4	12
8	Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan. <i>Infectious Diseases and Therapy</i> , 2022, 11, 485-500.	4.0	13
9	Ropeginterferon Alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 956-964.	1.7	15
10	Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan. <i>Hepatology International</i> , 2021, 15, 338-349.	4.2	20
11	Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan. <i>Liver International</i> , 2021, 41, 1265-1277.	3.9	29
12	Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 575-588.	8.9	9
13	Long-Term Safety in HBsAg-Negative, HBcAb-Positive Patients with Rheumatic Diseases Receiving Maintained Steroid Therapy after Pulse Therapy. <i>Journal of Clinical Medicine</i> , 2021, 10, 3296.	2.4	5
14	Evaluating the renal safety of tenofovir disoproxil fumarate in hepatitis B patients without chronic kidney disease. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1579-1586.	2.0	5
15	Establishing the blood reference interval of pancreatic elastase-1: A prospective study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, , .	2.8	1
16	Cessation of Nucleos(t)ide Analogue Therapy in Non-Cirrhotic Hepatitis B Patients with Prior Severe Acute Exacerbation. <i>Journal of Clinical Medicine</i> , 2021, 10, 4883.	2.4	3
17	Hepatitis C Virus-Induced Exosomal MicroRNAs and Toll-Like Receptor 7 Polymorphism Regulate B-Cell Activating Factor. <i>MBio</i> , 2021, 12, e0276421.	4.1	12
18	Hepatitis C virus reinfection in patients on haemodialysis after achieving sustained virologic response with antiviral treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, , .	3.7	9

#	ARTICLE	IF	CITATIONS
19	Drug Resistance Profile and Clinical Features for Hepatitis C Patients Experiencing DAA Failure in Taiwan. <i>Viruses</i> , 2021, 13, 2294.	3.3	4
20	Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan. <i>Scientific Reports</i> , 2021, 11, 23473.	3.3	8
21	Risk of hepatocellular carcinoma development after hepatitis C virus eradicated by direct-acting antivirals: Fact or fiction?. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 3-11.	1.7	19
22	High Risk of Clinical Relapse in Patients With Chronic Hepatitis B Virus Infection After Cessation of Prophylactic Antiviral Therapy for Rituximab-Containing Chemotherapy. <i>Journal of Infectious Diseases</i> , 2020, 222, 1345-1352.	4.0	6
23	Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis. <i>Scientific Reports</i> , 2020, 10, 9180.	3.3	8
24	Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment. <i>Journal of Viral Hepatitis</i> , 2020, 27, 568-575.	2.0	21
25	Oral direct acting antivirals treatment failed to cure a patient with chronic hepatitis C due to shifts of viral genotype. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 26, 203-206.	0.9	0
26	Association of virological breakthrough and clinical outcomes in entecavir-treated HBeAg-positive chronic hepatitis B. <i>PLoS ONE</i> , 2019, 14, e0221958.	2.5	2
27	Reactivation of hepatitis B virus infection following rituximab treatment in HBsAg-negative, HBcAb-positive rheumatoid arthritis patients: A long-term, real-world observation. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 1145-1151.	1.9	30
28	Specific adverse events predict survival rates in a Chinese population diagnosed with hepatocellular carcinoma and treated with sorafenib. <i>JGH Open</i> , 2019, 3, 10-16.	1.6	3
29	Sorafenib-Related Adverse Events in Predicting the Early Radiologic Responses of Hepatocellular Carcinoma. <i>Gastroenterology Research</i> , 2019, 12, 16-20.	1.3	7
30	Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1977-1983.	2.8	7
31	Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (LIFEPLUS 2). <i>Hepatology</i> , 2019, 70, 1336-1348.	7.3	111
32	Sorafenib treatment on Chinese patients with advanced hepatocellular carcinoma. <i>Medicine (United States)</i> , 2019, 98, 100000.	1.0	4
33	Comparisons of hepatitis C viral replication in patients with rheumatoid arthritis receiving tocilizumab, abatacept and tofacitinib therapy. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 849-850.	0.9	7
34	Risk-stratified management strategies for HBV reactivation in RA patients receiving biological and targeted therapy: A narrative review. <i>Journal of Microbiology, Immunology and Infection</i> , 2019, 52, 1-8.	3.1	26
35	The Ultra-Short Virological Dynamics in Response to Entecavir or Lamivudine during Chronic Hepatitis B with Spontaneous Severe Acute Exacerbation. <i>Antiviral Therapy</i> , 2018, 23, 77-85.	1.0	2
36	Risk factors and metabolic abnormality of patients with non-alcoholic fatty liver disease: Either non-obese or obese Chinese population. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2018, 17, 45-48.	1.3	27

#	ARTICLE	IF	CITATIONS
37	The prevalence and risk factors of hepatitis B flares in chronic hepatitis B patients receiving glucocorticoid pulse therapy. <i>International Journal of Clinical Pharmacy</i> , 2018, 40, 169-174.	2.1	7
38	Hepatitis B virus-related mortality in rheumatoid arthritis patients undergoing long-term low-dose glucocorticoid treatment: A population-based study. <i>Journal of the Formosan Medical Association</i> , 2018, 117, 566-571.	1.7	9
39	Association of hepatitis B virus infection and glomerulonephritis in a HBV endemic area: A population-based study. <i>Advances in Digestive Medicine</i> , 2018, 5, 121-126.	0.2	1
40	Prevalence of Hepatitis B Reactivation Among Chinese Individuals With Chronic Hepatitis C Treated With Pan-Oral Direct-Acting Antivirals. <i>Gastroenterology Research</i> , 2018, 11, 124-129.	1.3	10
41	The choice of antiviral therapy for hepatitis C recurrence after liver transplantation in the real world. <i>Journal of the Formosan Medical Association</i> , 2018, 117, 1036-1037.	1.7	0
42	Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study. <i>Scientific Reports</i> , 2018, 8, 13699.	3.3	22
43	On-treatment HBV DNA level could predict HBeAg seroclearance in patients with HBeAg-positive chronic hepatitis B with entecavir therapy. <i>Journal of the Chinese Medical Association</i> , 2017, 80, 341-346.	1.4	6
44	Lamivudine versus entecavir in the rescue of chemotherapy-induced hepatitis B flare-up. <i>Journal of the Chinese Medical Association</i> , 2017, 80, 758-765.	1.4	8
45	The association of non-alcoholic fatty liver disease and metabolic syndrome in a Chinese population. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2017, 16, 176-180.	1.3	18
46	Assessment of Educational Needs and Quality of Life of Chronic Hepatitis Patients. <i>BMC Health Services Research</i> , 2017, 17, 148.	2.2	8
47	Comparable Outcomes of Ultrasound versus Computed Tomography in the Guidance of Radiofrequency Ablation for Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2017, 12, e0169655.	2.5	28
48	On-treatment HBV DNA dynamics predict virological breakthrough in entecavir-treated HBeAg-positive chronic hepatitis B. <i>PLoS ONE</i> , 2017, 12, e0174046.	2.5	4
49	Oral Direct Acting Antivirals treatment failed to cure a patient with chronic hepatitis C due to shifts of viral genotype. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2017, 26, 205-206.	0.9	0
50	Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. <i>Liver International</i> , 2016, 36, 1755-1764.	3.9	177
51	Long-term Effects of Hepatitis B Immunization of Infants in Preventing Liver Cancer. <i>Gastroenterology</i> , 2016, 151, 472-480.e1.	1.3	187
52	Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection. <i>Hepatology International</i> , 2016, 10, 258-266.	4.2	9
53	Efficacy and resistance to telbivudine treatment in chronic hepatitis B patients with favorable predictors: a multicenter study in Taiwan. <i>Hepatology International</i> , 2016, 10, 294-301.	4.2	3
54	Sequential Treatment with Lamivudine and Peg-interferon Therapy in Patients with E-positive Chronic Hepatitis B and High Viral Load. <i>British Journal of Medicine and Medical Research</i> , 2016, 12, 1-8.	0.2	0

#	ARTICLE	IF	CITATIONS
55	Two-year Single-Center Real-Life Data of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B Patients in Taiwan. <i>Journal of Gastroenterology and Hepatology Research</i> , 2016, 5, 2010-2014.	0.2	0
56	Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trial. <i>Scientific Reports</i> , 2015, 5, 11710.	3.3	7
57	Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial. <i>Scientific Reports</i> , 2015, 5, 15255.	3.3	8
58	Asunaprevir-containing regimens for the treatment of hepatitis C virus infection. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 9-20.	3.0	6
59	The clinical efficacy and safety of EUSâ€FNA for diagnosis of mediastinal and abdominal solid tumors â€“ A single center experience. <i>Advances in Digestive Medicine</i> , 2015, 2, 61-66.	0.2	2
60	Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. <i>Gut</i> , 2015, 64, 303-311.	12.1	39
61	Risk of nonpsychotic mental disorders development in antiviral-treated mentally healthy chronic hepatitis C patients: A population-based study. <i>Journal of the Formosan Medical Association</i> , 2015, 114, 829-834.	1.7	3
62	Assessment of health-related quality of life in antiviral-treated Taiwanese chronic hepatitis C patients using SF-36 and CLDQ. <i>Health and Quality of Life Outcomes</i> , 2014, 12, 97.	2.4	25
63	Characteristics of Symptom Presentation and Risk Factors in Patients with Erosive Esophagitis and Nonerosive Reflux Disease. <i>Medical Principles and Practice</i> , 2014, 23, 460-464.	2.4	7
64	Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence. <i>World Journal of Gastroenterology</i> , 2014, 20, 11384.	3.3	55
65	Heartburn and regurgitation have different impacts on life quality of patients with gastroesophageal reflux disease. <i>World Journal of Gastroenterology</i> , 2014, 20, 12277.	3.3	22
66	Etiologies of Dyspepsia among a Chinese Population: One Hospital-Based Study. <i>Open Journal of Gastroenterology</i> , 2014, 04, 249-254.	0.1	2
67	A miniature ultrasound probe is useful in reducing rebleeding after endoscopic cyanoacrylate injection for hemorrhagic gastric varices. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 1347-1353.	1.5	10
68	Pegylated Interferon-Î±2a With or Without Low-Dose Ribavirin for Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Receiving Hemodialysis. <i>Annals of Internal Medicine</i> , 2013, 159, 729.	3.9	91
69	The impact of intravenous cefazolin to the outcomes of cirrhotic patients with esophageal varices bleeding. <i>Open Journal of Gastroenterology</i> , 2013, 03, 190-195.	0.1	0
70	Interleukin 28B Genetic Polymorphisms and Viral Factors Help Identify HCV Genotype-1 Patients who Benefit from 24-Week Pegylated Interferon plus Ribavirin Therapy. <i>Antiviral Therapy</i> , 2012, 17, 477-484.	1.0	41
71	Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin. <i>Antiviral Therapy</i> , 2012, 17, 1059-1067.	1.0	23
72	Effect of Host and Viral Factors on Hepatitis B E Antigen-Positive Chronic Hepatitis B Patients Receiving Pegylated Interferon-Î±2A Therapy. <i>Antiviral Therapy</i> , 2011, 16, 629-637.	1.0	91

#	ARTICLE	IF	CITATIONS
73	Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1719-1725.	0.9	159
74	Independent Factors Associated With Early Outcome in Chinese Cirrhotic Patients After Cessation of Initial Esophageal Variceal Hemorrhage. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, e123-e127.	2.2	9
75	Decreased Incidence of Hepatocellular Carcinoma in Hepatitis B Vaccinees: A 20-Year Follow-up Study. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1348-1355.	6.3	534
76	Geographic variations of predominantly hepatitis C virus associated male hepatocellular carcinoma townships in Taiwan: identification of potential high HCV endemic areas. <i>Hepatology International</i> , 2009, 3, 537-543.	4.2	11
77	Impact of the Tokyo guidelines on the management of patients with acute calculous cholecystitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 1857-1861.	2.8	84
78	Successful Application of Hemoclips plus Argon Plasma Coagulation for Angioectasia Bleeding with Underlying Arteriovenous Malformation in the Colon. <i>Colorectal Disease</i> , 2009, 12, e180-1.	1.4	2
79	Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage. <i>Journal of Hepatology</i> , 2009, 50, 958-968.	3.7	144
80	IL-10 promoter gene polymorphisms and sustained response to combination therapy in Taiwanese chronic hepatitis C patients. <i>Digestive and Liver Disease</i> , 2009, 41, 424-430.	0.9	35
81	<i>Mycoplasma pneumoniae</i> -associated Acute Hepatitis in an Adult Patient without Lung Infection. <i>Journal of the Chinese Medical Association</i> , 2009, 72, 204-206.	1.4	11
82	Factors Associated with Quality of Life in Chronic Hepatitis C Patients Who Received Interferon Plus Ribavirin Therapy. <i>Journal of the Formosan Medical Association</i> , 2008, 107, 454-462.	1.7	13
83	Pegylated Interferon-2a plus Ribavirin for Treatment-Naive Asian Patients with Hepatitis C Virus Genotype 1 Infection: A Multicenter, Randomized Controlled Trial. <i>Clinical Infectious Diseases</i> , 2008, 47, 1260-1269.	5.8	177
84	Retrospective Evaluation of Serum Markers APRI and AST/ALT for Assessing Liver Fibrosis and Cirrhosis in Chronic Hepatitis B and C Patients with Hepatocellular Carcinoma. <i>Internal Medicine</i> , 2008, 47, 569-575.	0.7	57
85	Long-term trends and geographic variations in the survival of patients with hepatocellular carcinoma: Analysis of 11312 patients in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, 1561-1566.	2.8	56
86	Changes of soluble CD26 and CD30 levels correlate with response to interferon plus ribavirin therapy in patients with chronic hepatitis C. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, 1789-1793.	2.8	18
87	Do young hepatocellular carcinoma patients have worse prognosis? The paradox of age as a prognostic factor in the survival of hepatocellular carcinoma patients. <i>Liver International</i> , 2006, 26, 766-773.	3.9	65
88	Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan. <i>International Journal of Cancer</i> , 2006, 119, 1946-1952.	5.1	120
89	Long-Term Results of Anti- <i>Helicobacter pylori</i> Therapy in Early-Stage Gastric High-Grade Transformed MALT Lymphoma. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1345-1353.	6.3	179
90	Long-term follow up of gastric low-grade mucosa-associated lymphoid tissue lymphoma by endosonography emphasizing the application of a miniature ultrasound probe. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2003, 18, 162-167.	2.8	25

#	ARTICLE	IF	CITATIONS
91	Mutations in the NS5A and E2-PePHD regions of hepatitis C virus genotype 1b and response to combination therapy of interferon plus ribavirin. <i>Liver International</i> , 2003, 23, 426-433.	3.9	19
92	Effect of P-glycoprotein and multidrug resistance associated protein gene expression on Tc-99m MIBI imaging in hepatocellular carcinoma. <i>Nuclear Medicine and Biology</i> , 2003, 30, 111-117.	0.6	11
93	Detection of the Hepatitis B Virus X Protein (HBx) Antigen and Anti-HBx Antibodies in Cases of Human Hepatocellular Carcinoma. <i>Journal of Clinical Microbiology</i> , 2003, 41, 5598-5603.	3.9	74
94	Mediation of transcatheter arterial chemoembolization induced gastric slow-wave dysrhythmia by endogenous prostaglandin1. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 17, 46-51.	2.8	2
95	7236 Endosonographic evaluation of low-grade gastric malt lymphoma- miniprobe sonography versus conventional endoscopic ultrasound.. <i>Gastrointestinal Endoscopy</i> , 2000, 51, AB302.	1.0	0
96	Endoscopic treatment of bleeding gastric varices by N-butyl-2-cyanoacrylate (Histoacryl) injection: long-term efficacy and safety. <i>Gastrointestinal Endoscopy</i> , 2000, 52, 160-167.	1.0	321
97	Migration of bird feather into bile duct mimicking bile duct stone recurrence: first ever case report. <i>Advances in Digestive Medicine</i> , 0, , .	0.2	0